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A 27−year−old woman presented with odynophagia and hematemesis. Her med− ical history was noteworthy for systemic lupus erythematosus for 9 years, steroid− induced psychosis, and operation for aseptic necrosis of the right femoral head. To prevent osteoporosis, she had been prescribed bisphosphonates. She said that she had been taking the tablet with an inadequate quantity of water. Re− sults of physical examination and routine blood examination were unremarkable. Endoscopy revealed vertical submucosal hematoma in the mid esophagus ( Fig−  ure 1) . Vertical fissures and circumferen− tial cracks with small, peeled, whitish mucosa were observed ( Figure 2) . A diag− nosis of esophagitis dissecans superficial− is associated with bisphosphonates was made. Discontinuation of the bisphospho− nates and administration of a proton pump inhibitor resulted in rapid recovery, and a repeat endoscopy after a week con− firmed complete healing of the esophagi− tis.
The causes of esophagitis dissecans su− perficialis include medications, hot bev− erages, chemical irritants, nasogastric in− tubation, and autoimmune bullous der− matosis (e. g. pemphigus vulgaris, mucous membrane pemphigoid). Bisphospho− nates, as well as potassium chloride and nonsteroidal anti−inflammatory drugs (NSAIDs), are one of the common causes of the esophagitis. Bisphosphonates have been widely prescribed to prevent and treat osteoporosis, but esophageal injury associated with the drugs was reported soon after their approval [1, 2] . Possible mechanisms underlying bisphosphonate− induced gastrointestinal events include prolonged contact of the crystalline coat− ing of the tablets with the mucosa, and di− rect erosive action by dissolved bisphos− phonates [3] . A synergistic ulcerogenic potential of concurrent bisphosphonates and NSAIDs should also be considered [4] . Endoscopic features of esophagitis dissecans superficialis vary from superfi− cial inflammation, esophageal cast or ul− ceration to stricture. To minimize esopha− geal injury, we should advise patients to take bisphosphonates with an adequate amount of water and to remain in an up− right posture for at least 30 minutes after swallowing the tablet. 
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